Outcome of the Management of Pulmonary Tuberculosis Patients with Treatment Failure from Standard Short Course Chemotherapy
Article Sidebar
Main Article Content
Abstract
Introduction : Tuberculosis(TB) is an infectious disease that is causing the deaths of people around the world. World Health Organization recommends the use of the Category II (2HRZES/1HRZE/5HRE) in the treatment of newly replicated for tuberculosis patients with treatment failure from Category I.The success rate of re-treatment with Category II in Thailand is relatively low (Success rate 42.8%) due to the problem of multiple drug resistance is increasing. So this study was to study the pattern of the re-treatment regimen, evaluate treatment outcome of anti-tuberculosis drug regimen of Category II, Second line drug or other regimen and test results of the sensitivity of drug resistant tuberculosis Material and method : Retrospective study was conducted in the hospital and tuberculosis center between October 1997 to September 2007. This study performed by collecting data from TB treatment card, TB registration book, TB laboratory register and OPD card and analyzed by descriptive statistics Results : The study sample of 249 patients treated over a relatively wide range. The most drugs used was Category II, followed by the second line drug. Category II, success rate was 63.9, failure rate was 11.1 and default was 6.1, Second line drug, success rate was 48.8, failure rate was 14 and default was 23.3. Re-treatment with HR (8 cases), and maintaining a system of Category I (8 cases), the success rate were 62.5 (5 of 8 cases) and failure 1 case and other drugs (10 cases), success rate were 40 (4 of 10 cases) and died 6 cases. The multi drug-resistant (MDR-TB) were 52 percent. Conclusion : Re-treatment outcome with various drugs in the study all Category II, the second line drugs or other regimens were below the global TB control (success at least 85%). However re-treatment outcome of category II is higher than other regimens.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Akeaura S, Kaseatchareon Y. Sputum conversion in patients with pulmonary tuberculosis patients treated repeatedly with Category II. Journal of Tuberculosis and Chest Disease. 2542; 20 (4): 267-273.
Department of Disease Control Ministry of Health. National guidelines for tuberculosis control. Bangkok: Printing Office of National Buddhism. 2005; 1-3, 23-38, 59-661.
Department of Disease Control Ministry of Health. National guidelines for tuberculosis control. Printing 2 (revised). Bangkok: Printing Office of National Buddhism; 2008: 1-3, 31-48, 59-78.
Department of Public Health. National guidelines for the treatment of multidrug-resistant tuberculosis Augsorn graphics and design; 2008; 1-12.
Gninafon M, Tawo L, Kassa F, Monteiro GP, Zellweger JP and Shang H. Outcome of tuberculosis retreatment in routine conditions in Cotonou, Benin. The International Journal of Tuberculosis and Lung D/sease.2004; 8(10): 1242-1247.
Harries AD, Nyirenda TE, Kemp JR, Squire BS, Godfrey- Faussett p and Salaniponi FML. Management and outcome of tuberculosis patients who fail treatment under routine programme conditions in Malawi. The International Journal of Tuberculosis and Lung Disease.2003;7(11): 1040-1044.
Heldal E, Arnadottir T, Cruz JR, Tardencilla A and Chacon L. Low failure rate In standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and Survival of ‘Chronic’ pateints. The International Journal of Tuberculosis and Lung Disease.2001; 5(2): 129-136.
Hreantrirat p, Chalasonthi M and Warakaseamsuk p. The evaluation of patients with pulmonary tuberculosis, the use of CAT 2 (2HRZES/1HRZE/ 5HRE) and TB patients who use drugs. CAT 4 (second line drug) at the Bureau of AIDS TB. Tuberculosis and sexually transmitted diseases. Journal of Tuberculosis, Chest and medical treatment of the crisis. 2007; 27 (3): 217-229.
Kankawinpong o. Effectiveness of TB treatment 2HRZES/1HRZE/5HRE. Journal of Tuberculosis and Chest Disease. 2545; 23 (3): 107-114.
Kelly PM., Lumb R, Pinto A, Costa GD, Sarmento J and Bastian I. Analysis, of Mycobacterium tuberculosis isolates from treatment failure patients living in East Timor. The International Journal of Tuberculosis and Lung Disease. 2005; 9(1): 81-86.
Kunkritsada C. The treatment of tuberculosis patients treated in Pahonponpayuhasana Fiscal year 2007-2008. Journal of Public Health. 2541; 17(3) :777- 784.
ottmani SE, Zignol M, Bencheikh N, Laasri L, Chaouki N and Mahjour J. Results of cohort analysis by category of tuberculosis retreatment cased in Morocco from 1996 to 2003. The International Journal of Tuberculosis and Lung D/sease.2006; 10(12): 1367-1372.
Saravia JC, Appleton sc, Rich ML, Sarria M, Bayona J and Beceerra MC. Retreatment management strategies when first-line tuberculosis therapy fails. The International Journal of Tuberculosis and Lung D/sease.2005;9(4):421-429.
World Health Organization. Treatment of tuberculosis: Guideline for national programme. 2nd ed., Geneva: World Health Organization,1997.
World Health Organization. Treatment of tuberculosis: Guidelines for national programes, 3nd ed., Geneva: World Health Organization,2003.
World Health Organization. Anti-tuberculosis Drug Resistance in the World. Report: WHO report [WHO/HTM/TB/2008.394]. Geneva: World Health Organization, 2003.
World Health Organization. Treatment of tuberculosis: Guideline for national programme. 2nd ed., Geneva: World Health Organization, 2010.